Medicines Company

Melinta Therapeutics to acquire Infectious Disease Business from The Medicines Company

Monday, December 4, 2017

Melinta Therapeutics, a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial infections, announced that Melinta and The Medicines Company have entered into an agreement pursuant to which Melinta will acquire the infectious disease business from The Medicines Company. This includes three marketed products: recently approved and launched Vabomere (vaborbactam/meropenem), and established commercial products Orbactiv (oritavancin) and Minocin IV (minocycline). 

[Read More]

Da Volterra, The Medicines Company join COMBACTE-NET to combat antimicrobial resistance

Friday, November 18, 2016

The Innovative Medicines Initiative (IMI)-funded New Drugs 4 Bad Bugs (ND4BB) project COMBACTE-NET announces that two new pharmaceutical companies, Da Volterra and The Medicines Company, have joined the project as partners. Together with the existing partners the new partners will closely collaborate to further strengthen the public-private partnership aiming to combat the worldwide growing problem of antimicrobial resistance.

[Read More]

The Medicines Company acquires Annovation Biopharma

Thursday, February 5, 2015

The Medicines Company has completed its acquisition of all of the outstanding equity of Annovation Biopharma, a company focused on creating more effective, safer therapies for anesthesia and critical care. Based on technology licensed from Massachusetts General Hospital, Annovation is developing ABP-700, a novel intravenous anesthetic which in phase I clinical studies has demonstrated potent and rapidly reversible anesthetic effects.

[Read More]